BRAF and carcinoma: Here, through mutation analysis, we provide insight into the somatically altered genes of MOTs, identifying many candidates not previously implicated in this disease, including a higher than expected proportion of carcinomas with TP53 and BRAF mutations, as well as the prevalent RAS pathway mutations and loss of p16.